Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 134-138 , March 2010

Mammalian target of rapamycin: A new target in prostate cancer

Received 30 January 2009 ,Revised 18 March 2009 ,Accepted 19 March 2009.

References 

  1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  3. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–826
  4. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758
  5. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996;14:483–510
  6. Tee R, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and −2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA. 2002;99:13571–13576
  7. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol. 2002;4:648–657
  8. Abraham T. Identification of TOR signaling complexes: More TORC for the cell growth engine. Cell. 2002;111:9–12
  9. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004;10:6572–6578
  10. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64:5232–5236
  11. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–2963
  12. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000;1470:M21–M35
  13. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302
  14. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science. 2005;307:1098–1101
  15. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–845
  16. Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell. 2002;13:1792–1801
  17. Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282:20534–20543
  18. Morice WG, Brunn GJ, Wiederrecht G, et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem. 1993;268:3734–3738
  19. Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer. 2004;91:1420–1424
  20. Barbet NC, Schneider U, Helliwell SB, et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell. 1996;7:25–42
  21. Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003;29:171–187
  22. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 1998;18:6711–6718
  23. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 2006;66:1203–1212
  24. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA. 2000;97:14340–14345
  25. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Comprehensive Cancer Network. 2008;6(Suppl 5):S1–S20
  26. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65:2825–2831
  27. Wang Y, Mikhailova M, Bose S, et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27:7106–7117
  28. Gao H, Outang X, Banach-Petrosky WA, et al. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA. 2006;103:14477–14482
  29. Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003;310:1124–1132
  30. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate. Eur J Cancer. 2005;41:846–857
  31. Itoh S, Jtoh F, Goumans MJ, et al. Signaling of transforming growth factor-β family members through SMAD proteins. Eur J Biochem. 2000;267:6954–6967
  32. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor-β in human disease. N Engl J Med. 2000;342:1350–1358
  33. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog. 1993;4:493–540
  34. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev. 1996;7:93–102
  35. van der Poel HG, Hanrahan C, Zhong H, et al. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res. 2003;30:380–386
  36. van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells. J Urol. 2004;172(4 Pt 1):1333–1337
  37. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  38. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon α for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958–3964
  39. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–918

PII: S1078-1439(09)00097-0

doi: 10.1016/j.urolonc.2009.03.023

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 134-138 , March 2010

Article Tools

* Image Usage & Resolution